Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rosanò L[au]:

New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis. Bagnato A et al. Front Pharmacol. (2019)

Endothelin 1 in cancer: biological implications and therapeutic opportunities. Rosanò L et al. Nat Rev Cancer. (2013)

Targeting endothelin-1 receptor/β-arrestin1 network for the treatment of ovarian cancer. Rosanò L et al. Expert Opin Ther Targets. (2017)

Search results

Items: 1 to 50 of 81

1.

Targeting Endothelin-1 Receptor/β-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach.

Tocci P, Rosanò L, Bagnato A.

Front Endocrinol (Lausanne). 2019 Sep 4;10:609. doi: 10.3389/fendo.2019.00609. eCollection 2019. Review.

2.

β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer.

Tocci P, Cianfrocca R, Di Castro V, Rosanò L, Sacconi A, Donzelli S, Bonfiglio S, Bucci G, Vizza E, Ferrandina G, Scambia G, Tonon G, Blandino G, Bagnato A.

Nat Commun. 2019 Jul 19;10(1):3196. doi: 10.1038/s41467-019-11045-8.

3.

New insights into the regulation of the actin cytoskeleton dynamics by GPCR/β-arrestin in cancer invasion and metastasis.

Rosanò L, Bagnato A.

Int Rev Cell Mol Biol. 2019;346:129-155. doi: 10.1016/bs.ircmb.2019.03.002. Epub 2019 Apr 13.

PMID:
31122393
4.

Methods to Investigate β-Arrestin-1/β-Catenin Signaling in Ovarian Cancer Cells.

Rosanò L, Cianfrocca R, Bagnato A.

Methods Mol Biol. 2019;1957:393-406. doi: 10.1007/978-1-4939-9158-7_25.

PMID:
30919368
5.

New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis.

Bagnato A, Rosanò L.

Front Pharmacol. 2019 Feb 19;10:114. doi: 10.3389/fphar.2019.00114. eCollection 2019. Review.

6.

Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer.

Chellini L, Caprara V, Spadaro F, Sestito R, Bagnato A, Rosanò L.

Matrix Biol. 2019 Aug;81:17-33. doi: 10.1016/j.matbio.2018.10.005. Epub 2018 Oct 25.

7.

In reply to Schäfer et al: new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma.

Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, Scupoli MT, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C.

Br J Haematol. 2019 Mar;184(6):1052-1055. doi: 10.1111/bjh.15240. Epub 2018 May 4. No abstract available.

PMID:
29726006
8.

hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.

Di Modugno F, Caprara V, Chellini L, Tocci P, Spadaro F, Ferrandina G, Sacconi A, Blandino G, Nisticò P, Bagnato A, Rosanò L.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3132-3137. doi: 10.1073/pnas.1715998115. Epub 2018 Feb 8.

9.

Targeting endothelin-1 receptor/β-arrestin1 network for the treatment of ovarian cancer.

Rosanò L, Cianfrocca R, Sestito R, Tocci P, Di Castro V, Bagnato A.

Expert Opin Ther Targets. 2017 Oct;21(10):925-932. doi: 10.1080/14728222.2017.1361930. Epub 2017 Sep 5. Review.

PMID:
28758529
10.

Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer.

Cianfrocca R, Rosanò L, Tocci P, Sestito R, Caprara V, Di Castro V, De Maria R, Bagnato A.

Cell Death Differ. 2017 Oct;24(10):1811-1820. doi: 10.1038/cdd.2017.121. Epub 2017 Jul 14.

11.

Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.

Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, Scupoli MT, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C.

Br J Haematol. 2017 Sep;178(5):781-793. doi: 10.1111/bjh.14771. Epub 2017 Jun 9.

PMID:
28597546
12.

Endothelin-1 receptor drives invadopodia: Exploiting how β-arrestin-1 guides the way.

Bagnato A, Rosanò L.

Small GTPases. 2018 Sep 3;9(5):394-398. doi: 10.1080/21541248.2016.1235526. Epub 2016 Oct 3. Review.

13.

β-arrestin1 at the cross-road of endothelin-1 signaling in cancer.

Rosanò L, Bagnato A.

J Exp Clin Cancer Res. 2016 Jul 29;35(1):121. doi: 10.1186/s13046-016-0401-4. Review.

14.

Disrupting the endothelin and Wnt relationship to overcome chemoresistance.

Rosanò L, Bagnato A.

Mol Cell Oncol. 2015 Jan 30;2(3):e995025. doi: 10.4161/23723556.2014.995025. eCollection 2015 Jul-Sep.

15.

Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression.

Cianfrocca R, Tocci P, Rosanò L, Caprara V, Sestito R, Di Castro V, Bagnato A.

Oncotarget. 2016 Apr 5;7(14):17790-804. doi: 10.18632/oncotarget.7461.

16.

Endothelin therapeutics in cancer: Where are we?

Rosanò L, Bagnato A.

Am J Physiol Regul Integr Comp Physiol. 2016 Mar 15;310(6):R469-75. doi: 10.1152/ajpregu.00532.2015. Epub 2016 Jan 27. Review.

17.

Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer.

Tocci P, Caprara V, Cianfrocca R, Sestito R, Di Castro V, Bagnato A, Rosanò L.

Life Sci. 2016 Aug 15;159:49-54. doi: 10.1016/j.lfs.2016.01.008. Epub 2016 Jan 8.

PMID:
26776837
18.

Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.

Sestito R, Cianfrocca R, Rosanò L, Tocci P, Di Castro V, Caprara V, Bagnato A.

Life Sci. 2016 Aug 15;159:43-48. doi: 10.1016/j.lfs.2016.01.009. Epub 2016 Jan 8.

PMID:
26776834
19.

miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.

Sestito R, Cianfrocca R, Rosanò L, Tocci P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A, Blandino G, Bagnato A.

Oncotarget. 2016 Jan 26;7(4):4009-23. doi: 10.18632/oncotarget.6546.

20.

Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma.

Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Veglione M, Castro VD, Spadaro F, Ferrandina G, Bagnato A, Rosanò L.

Oncogene. 2016 Jun 30;35(26):3432-42. doi: 10.1038/onc.2015.403. Epub 2015 Nov 2.

PMID:
26522724
21.

Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy.

Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A.

Cancer Res. 2014 Dec 15;74(24):7453-64. doi: 10.1158/0008-5472.CAN-13-3133. Epub 2014 Nov 6.

22.

Endothelin-1 regulates hypoxia-inducible factor-1α and -2α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells.

Caprara V, Scappa S, Garrafa E, Di Castro V, Rosanò L, Bagnato A, Spinella F.

Life Sci. 2014 Nov 24;118(2):185-90. doi: 10.1016/j.lfs.2014.02.030. Epub 2014 Mar 6.

23.

β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells.

Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A, Rosanò L.

Life Sci. 2014 Nov 24;118(2):179-84. doi: 10.1016/j.lfs.2014.01.078. Epub 2014 Feb 12.

24.

The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.

Spinella F, Caprara V, Cianfrocca R, Rosanò L, Di Castro V, Garrafa E, Natali PG, Bagnato A.

Carcinogenesis. 2014 Apr;35(4):840-8. doi: 10.1093/carcin/bgu018. Epub 2014 Jan 28.

25.

β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury.

Buelli S, Rosanò L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, Perico L, Conti S, Rizzo P, Novelli R, Morigi M, Zoja C, Remuzzi G, Bagnato A, Benigni A.

J Am Soc Nephrol. 2014 Mar;25(3):523-33. doi: 10.1681/ASN.2013040362. Epub 2013 Dec 26.

26.

Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Rosanò L, Spinella F, Bagnato A.

Nat Rev Cancer. 2013 Sep;13(9):637-51. doi: 10.1038/nrc3546. Epub 2013 Jul 25. Review.

PMID:
23884378
27.

β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.

Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, Salvati E, Biroccio AM, Natali PG, Bagnato A.

Oncogene. 2013 Oct 17;32(42):5066-77. doi: 10.1038/onc.2012.527. Epub 2012 Dec 3.

PMID:
23208497
28.

Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.

Spinella F, Caprara V, Di Castro V, Rosanò L, Cianfrocca R, Natali PG, Bagnato A.

J Mol Med (Berl). 2013 Mar;91(3):395-405. doi: 10.1007/s00109-012-0956-2. Epub 2012 Sep 11.

PMID:
22965194
29.

Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.

Garrafa E, Caprara V, Di Castro V, Rosanò L, Bagnato A, Spinella F.

Life Sci. 2012 Oct 15;91(13-14):638-43. doi: 10.1016/j.lfs.2012.03.033. Epub 2012 Apr 13.

30.

The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.

Cianfrocca R, Tocci P, Spinella F, Di Castro V, Bagnato A, Rosanò L.

Life Sci. 2012 Oct 15;91(13-14):550-6. doi: 10.1016/j.lfs.2012.03.023. Epub 2012 Mar 28.

31.

Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis.

Bagnato A, Rosanò L.

Curr Oncol. 2012 Feb;19(1):36-8. doi: 10.3747/co.19.895. No abstract available.

32.

Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.

Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A.

Clin Cancer Res. 2011 Apr 15;17(8):2350-60. doi: 10.1158/1078-0432.CCR-10-2325. Epub 2011 Jan 10.

33.

Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase.

Cianfrocca R, Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A.

Can J Physiol Pharmacol. 2010 Aug;88(8):796-801. doi: 10.1139/Y10-052.

34.

Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells.

Spinella F, Caprara V, Garrafa E, Di Castro V, Rosanò L, Natali PG, Bagnato A.

Can J Physiol Pharmacol. 2010 Aug;88(8):782-7. doi: 10.1139/Y10-050.

35.

Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.

Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Natali PG, Bagnato A.

Can J Physiol Pharmacol. 2010 Jun;88(6):676-81. doi: 10.1139/Y10-053.

36.

Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.

Spinella F, Rosanò L, Del Duca M, Di Castro V, Nicotra MR, Natali PG, Bagnato A.

PLoS One. 2010 Jun 21;5(6):e11241. doi: 10.1371/journal.pone.0011241.

37.

The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer.

Rosanò L, Spinella F, Bagnato A.

Am J Physiol Regul Integr Comp Physiol. 2010 Aug;299(2):R395-404. doi: 10.1152/ajpregu.00304.2010. Epub 2010 Jun 10. Review.

38.

Convergent pathways link the endothelin A receptor to the beta-catenin: the beta-arrestin connection.

Rosanò L, Bagnato A.

Cell Cycle. 2009 May 15;8(10):1462-3. Epub 2009 May 25. No abstract available.

PMID:
19395853
39.

Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.

Spinella F, Garrafa E, Di Castro V, Rosanò L, Nicotra MR, Caruso A, Natali PG, Bagnato A.

Cancer Res. 2009 Mar 15;69(6):2669-76. doi: 10.1158/0008-5472.CAN-08-1879. Epub 2009 Mar 10.

40.

Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.

Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11. doi: 10.1073/pnas.0807158106. Epub 2009 Feb 6.

41.

The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.

Bagnato A, Spinella F, Rosanò L.

Can J Physiol Pharmacol. 2008 Aug;86(8):473-84. doi: 10.1139/Y08-058. Review.

42.

The endothelin axis in cancer.

Bagnato A, Rosanò L.

Int J Biochem Cell Biol. 2008;40(8):1443-51. doi: 10.1016/j.biocel.2008.01.022. Epub 2008 Feb 1. Review.

PMID:
18325824
43.

Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.

Folgiero V, Avetrani P, Bon G, Di Carlo SE, Fabi A, Nisticò C, Vici P, Melucci E, Buglioni S, Perracchio L, Sperduti I, Rosanò L, Sacchi A, Mottolese M, Falcioni R.

PLoS One. 2008 Feb 13;3(2):e1592. doi: 10.1371/journal.pone.0001592.

44.
45.

Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.

Rosanò L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, Bagnato A.

Cancer Res. 2007 Jul 1;67(13):6351-9.

46.

Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.

Bagnato A, Rosanò L.

Cells Tissues Organs. 2007;185(1-3):85-94. Review.

PMID:
17587812
47.

Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells.

Spinella F, Rosanò L, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A.

Cancer Res. 2007 Feb 15;67(4):1725-34.

48.

Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.

Spinella F, Rosanò L, Di Castro V, Decandia S, Albini A, Nicotra MR, Natali PG, Bagnato A.

Mol Cancer Ther. 2006 Jun;5(6):1483-92.

49.

ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.

Rosanò L, Di Castro V, Spinella F, Decandia S, Natali PG, Bagnato A.

Exp Biol Med (Maywood). 2006 Jun;231(6):1132-5.

PMID:
16741063
50.

Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.

Rosanò L, Spinella F, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A.

Exp Biol Med (Maywood). 2006 Jun;231(6):1128-31.

PMID:
16741062

Supplemental Content

Loading ...
Support Center